Navigation Links
ActiPatch(TM) Granted Market Clearance by the Food & Drug Administration in the Kingdom of Jordan
Date:11/14/2007

BioElectronics Initiates Both Retail and Medical Product Shipments Into

Jordan

FREDERICK, Md., Nov. 14 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (OTC Pink Sheets: BIEL), announced today that the Jordan Food & Drug Administration has cleared ActiPatch for sale. The Company has initiated shipments for both the retail and the medical professional markets into the Kingdom.

"We are proud to announce another step for our Company in introducing the pain relief and healing benefits of ActiPatch to the international market. We are working closely with Distinction Corporation and excited to include them in our growing list of distributors. I have every confidence that this new relationship will bring not only success to our two companies in the Kingdom of Jordan, but also additional expansion into other Middles East markets," said Andrew Whelan, President of BioElectronics Corporation.

Farid Tamini, President of Distinction Corporation, said, "With the approval process behind us, we will quickly launch this wonderful product in the Kingdom of Jordan. We are pleased to be working with BioElectronics. There is an air of enthusiasm for this unique drug free therapy that will surely multiply as the medical professionals and patients experience the benefits of ActiPatch."

About BioElectronics:

BioElectronics Corporation is the maker of ActiPatch. ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.

For more information visit http://www.bioelectronicscorp.com

Safe Harbor Statement:

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
2. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
3. USC granted $8.4 million for autism research
4. Aida Granted Additional Anti-Cancer Patent
5. CME LLC Granted Five-Year Full Approval by the American Psychological Association
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
10. Sodexho, Inc. Announces Patrick E. Connolly as Market President & COO
11. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... Woodinville, WA (PRWEB) , ... May 05, 2016 ... ... better user experience, adapted to people’s every day living patterns, Amerec, a Seattle-based ... easy-to-use computer and smart phone app. , The user interface of the app, ...
(Date:5/5/2016)... ... May 05, 2016 , ... In honor of National Nurses Week ... all over the United States to thank a nurse who's made a difference in ... $5 to the American Red Cross of San Diego/Imperial Counties (up to $10,000) every ...
(Date:5/5/2016)... ... May 05, 2016 , ... When stiff and achy joints ... the pain that’s a common osteoarthritis (OA) symptom. Yet, numerous clinical studies point ... arthritis. , “Physical therapy exercises are commonly prescribed to individuals with osteoarthritis ...
(Date:5/5/2016)... ... May 05, 2016 , ... Chronic stress can have a silent, yet ... weaken the immune system and increase inflammation, both of which raise the risk of ... congenital heart disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can lead ...
(Date:5/5/2016)... ... May 05, 2016 , ... VisualDx announced today ... VisualDx is the first point of care diagnostic support system to be widely ... system speeds diagnosis, therapy decisions and patient education for emergency physicians, hospitalists and ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... Conn., May 4, 2016  Compass Diversified Holdings (NYSE: ... "Company"), an owner of leading middle market businesses, announced ... ended March 31, 2016. First Quarter 2016 ... and Reinvestment ("CAD" or "Cash Flow") of $13.6 million ... net loss of $15.0 million for the first quarter ...
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Myeloid Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Myeloid Leukemia epidemiology, Acute Myeloid ...
Breaking Medicine Technology: